2 results
Approved WMOPending
Primary Objective: The primary objective is to investigate whether EUS-TCB had an added value on EUS-FNA alone. Secondary Objective(s): The secondary objective is to study whether EUS-TCB does not have a higher complication rate than EUS-FNA alone.
Approved WMORecruiting
To determine a safe dose combination of carboplatin-cyclophosphamide combined with atezolizumab fixed dose in advanced breast cancer and gynaecologic cancer (ovarian, cervical and endometrial cancer).